Clinical trial
DX-8951f in Treating Women Who Have Advanced or Recurrent Cancer of the Cervix
NCT00004866 · Daiichi Sankyo, Industry · Completed
Key facts
| NCT number | NCT00004866 |
|---|---|
| Title | DX-8951f in Treating Women Who Have Advanced or Recurrent Cancer of the Cervix |
| Official title | A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Advanced or Recurrent Squamous Cell Cancer of the Cervix |
| Lead sponsor | Daiichi Sankyo, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cervical Cancer |
| Intervention type | Drug |
| Interventions | exatecan mesylate |
| Start date | Jan 1, 2000 |
| Primary completion | Sep 1, 2003 |
| Completion | Sep 1, 2003 |
| First posted | Jan 27, 2003 |
| Last update posted | May 16, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: